(studies are just copy-pasted)
Study 1 — U.S. Phase 3 Pivotal Trial
Source: Allergan/Latisse Phase 3 RCT · N=278 adults · 16 weeks · double-blind, placebo-controlled
PubMed PMID: 21899919 · ClinicalTrials.gov: NCT00693420
Primary endpoint — GEA (Global Eyelash Assessment):
≥1-point improvement on the GEA scale — 78.1% (bimatoprost) vs. 18.4% (placebo) at Week 16 (P<0.0001).
Secondary endpoints—DIA (Digital Image Analysis):
By week 16, bimatoprost resulted in a mean increase in eyelash length of +25% versus +2% for placebo, a mean increase in thickness of +106% versus +12%, and a mean increase in darkness of +18%.
Absolute length values (ClinicalTrials.gov NCT00693420):
By week 20 (post-treatment), the mean increase in length was +1.47 mm (bimatoprost, n=137) versus +0.06 mm (placebo, n=141).
Temporal dynamics:
Eyelash length increased statistically significantly starting at week 4; thickness and darkening—starting at week 8.
Study 2 — Post-chemotherapy, 12 months
Source: Wirta et al. · PubMed PMID: 26060513 · absolute value data from Allergan’s patent dossier (USPTO 8758733)
Length (absolute values):
Baseline length: 4.86 mm → increase of +1.99 mm by the 6th month. Mean percentage increase: +48.08% (6 months) and +49.88% (12 months); median increase: +37.84% (6 months) and +39.08% (12 months).
Thickness (absolute values):
Baseline thickness: 0.39 mm² → increase of +0.83 mm² by month 6.
Responder rate:
Responder rate: 46.9% (bimatoprost) versus 18.2% (placebo) at 6 months (P=0.004); at 12 months—61.5% among those who continued bimatoprost.
Study 3 — Japanese cohorts (idiopathic + post-chemotherapy)
Source: Springer Aesthetic Plastic Surgery · PMC4003339 · two parallel groups, N=173 (idiopathic) + N=36 (post-chemotherapy)
Idiopathic (Study 1):
Mean increase by the 4th month: length +1.62 mm (+24%), thickness +0.35 mm² (+44.8%), pigmentation -12.02 IU (8% darker).
Post-chemotherapy (Study 2):
Significant between-group differences by month 4: length +2.65 mm (bimatoprost) vs. +0.99 mm (placebo) (P=0.003); thickness +0.76 mm² vs. +0.28 mm² (P=0.007).
GEA:
GEA score ≥1: 77.3% vs. 17.6% (idiopathic, P<0.001) and 88.9% vs. 27.8% (post-chemotherapy, P<0.001).
Study 4 — Japanese cohort, DIA data on length and thickness
Source: ClinicalTrials.gov NCT01391273 · n=88 bimatoprost / n=85 placebo
Baseline length: 6.92±0.81 mm (bimatoprost) and 7.00±0.83 mm (placebo). By month 4: increase of +1.62±1.11 mm vs. -0.04±0.36 mm.
Baseline thickness: 0.98 ± 0.32 mm² (bimatoprost) and 1.01 ± 0.33 mm² (placebo). By the 4th month: increase of +0.35 ± 0.31 mm² vs. -0.03 ± 0.20 mm².
Study 1 — U.S. Phase 3 Pivotal Trial
Source: Allergan/Latisse Phase 3 RCT · N=278 adults · 16 weeks · double-blind, placebo-controlled
PubMed PMID: 21899919 · ClinicalTrials.gov: NCT00693420
Primary endpoint — GEA (Global Eyelash Assessment):
≥1-point improvement on the GEA scale — 78.1% (bimatoprost) vs. 18.4% (placebo) at Week 16 (P<0.0001).
Secondary endpoints—DIA (Digital Image Analysis):
By week 16, bimatoprost resulted in a mean increase in eyelash length of +25% versus +2% for placebo, a mean increase in thickness of +106% versus +12%, and a mean increase in darkness of +18%.
Absolute length values (ClinicalTrials.gov NCT00693420):
By week 20 (post-treatment), the mean increase in length was +1.47 mm (bimatoprost, n=137) versus +0.06 mm (placebo, n=141).
Temporal dynamics:
Eyelash length increased statistically significantly starting at week 4; thickness and darkening—starting at week 8.
Study 2 — Post-chemotherapy, 12 months
Source: Wirta et al. · PubMed PMID: 26060513 · absolute value data from Allergan’s patent dossier (USPTO 8758733)
Length (absolute values):
Baseline length: 4.86 mm → increase of +1.99 mm by the 6th month. Mean percentage increase: +48.08% (6 months) and +49.88% (12 months); median increase: +37.84% (6 months) and +39.08% (12 months).
Thickness (absolute values):
Baseline thickness: 0.39 mm² → increase of +0.83 mm² by month 6.
Responder rate:
Responder rate: 46.9% (bimatoprost) versus 18.2% (placebo) at 6 months (P=0.004); at 12 months—61.5% among those who continued bimatoprost.
Study 3 — Japanese cohorts (idiopathic + post-chemotherapy)
Source: Springer Aesthetic Plastic Surgery · PMC4003339 · two parallel groups, N=173 (idiopathic) + N=36 (post-chemotherapy)
Idiopathic (Study 1):
Mean increase by the 4th month: length +1.62 mm (+24%), thickness +0.35 mm² (+44.8%), pigmentation -12.02 IU (8% darker).
Post-chemotherapy (Study 2):
Significant between-group differences by month 4: length +2.65 mm (bimatoprost) vs. +0.99 mm (placebo) (P=0.003); thickness +0.76 mm² vs. +0.28 mm² (P=0.007).
GEA:
GEA score ≥1: 77.3% vs. 17.6% (idiopathic, P<0.001) and 88.9% vs. 27.8% (post-chemotherapy, P<0.001).
Study 4 — Japanese cohort, DIA data on length and thickness
Source: ClinicalTrials.gov NCT01391273 · n=88 bimatoprost / n=85 placebo
Baseline length: 6.92±0.81 mm (bimatoprost) and 7.00±0.83 mm (placebo). By month 4: increase of +1.62±1.11 mm vs. -0.04±0.36 mm.
Baseline thickness: 0.98 ± 0.32 mm² (bimatoprost) and 1.01 ± 0.33 mm² (placebo). By the 4th month: increase of +0.35 ± 0.31 mm² vs. -0.03 ± 0.20 mm².

